Advertisement

Journal of Neuro-Oncology

, Volume 50, Issue 3, pp 265–273 | Cite as

Cerebral Metastases as First Symptom of Cancer: a Clinico-pathologic Study

  • Maria Teresa Giordana
  • Susanna Cordera
  • Andrea Boghi
Article

Abstract

Symptomatic brain metastases of carcinomas in patients without a previously diagnosed malignancy are frequent in neurosurgical series. Such tumors often lack distinctive morphological characteristics so that the routine histological examination can be unsuccessful in identifying the site of origin. Objectives of the present study were to evaluate the frequency of brain metastases as the only manifestation of an unknown primary cancer by the retrospective analysis of a series of consecutively operated single cerebral metastases; to verify the efficacy of clinical investigations in detecting the site of origin; to investigate whether the primary site can be identified by the immunohistochemical study of the neurosurgical specimens. Antibodies to the following antigens were used: carcinoembryonic antigen (CEA), carbohydrate antigen (CA)19.9, CA125, BCA-225, cytokeratin 20, PSA, HMB-45. Out of 181 patients operated for single cerebral metastasis of carcinoma, 99 (54.7%) were in patients without any previously diagnosed systemic neoplasm. In 26.7% the primary remained undiagnosed after clinical investigations, in 9 cases even at autopsy. PSA and HMB45 antibodies specifically identified metastases from prostate carcinomas and skin melanomas, respectively. No other specific immunophenotype was identified; the immunoreactivity of the single cases was more or less suggestive for a primary site. Precocious metastases of lung carcinomas expressed CEA more frequently than late metastases. It has been hypothesized that CEA plays some role as a contact mediating device. CEA expression can have some link with the tendency to metastasize precociously to the brain. No major difference of p53 and k-ras expression has been found in precocious versus late brain metastases.

cerebral metastases immunohistochemistry CEA p53 k-ras 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nussbaum ES, Djalilian HR, Cho KH, Hall WA: Brain metastases. Histology, multiplicity, surgery and survival. Cancer 78: 1781-1788, 1996Google Scholar
  2. 2.
    Salvati M, Cervoni L, Raco A: Single brain metastases from unknown primary malignancies in CT-era. J Neuro-Oncol 23: 75-80, 1995Google Scholar
  3. 3.
    Macchiarini P, Buonaguidi R, Hardin M, Mussi A, Angeletti CA: Results and prognostic factors of surgery in the management of non-small cell lung cancer with solitary brain metastasis. Cancer 68: 300-304, 1991Google Scholar
  4. 4.
    Lonjon M, Paquis P, Michiels JF, Frenay M, Bensadoun RJ, Chatel M, Roche JL, Grellier P: Métastases cérébrales uniques des cancers broncho-pulmonaires. Rev Neurol (Paris) 150: 216-221, 1994Google Scholar
  5. 5.
    Le Chevalier T, Smith FP, Caille P, Constans JP, Rouesse JG: Sites of primary malignancies in patients presenting with cerebral metastases. A review of 120 cases. Cancer 56: 880-882, 1985Google Scholar
  6. 6.
    Merchut MP: Brain metastases from undiagnosed systemic neoplasms. Arch Intern Med 149: 1076-1080, 1989Google Scholar
  7. 7.
    van de Pol M, van Aalst VC, Wilmink JT, Twijnstra A: Brain metastases from an unknown primary tumour: which diagnostic procedures are indicated? J Neurol Neurosurg Psychiatry 61: 321-323, 1996Google Scholar
  8. 8.
    Nguyen LN, Maor MH, Oswald MJ: Brain metastases as the only manifestation of an undetected primary tumor. Cancer 83: 2181-2184, 1998Google Scholar
  9. 9.
    Le Cesne A, Le Chevalier T, Caille P, Cvitkovic E, Contesso G, Spielmann M, Rouesse J: Métastases de cancer à point de départ inconnue. Enseignement de 302 autopsies. Presse Med 20: 1369-1373, 1991Google Scholar
  10. 10.
    Brown RW, Brozo Campagna L, Dunn JK, Cagle PT: Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. Am J Clin Pathol 107: 12-19, 1997Google Scholar
  11. 11.
    Perry A, Parisi JE, Kurtin PJ: Metastatic adenocarcinoma to the brain: an immunohistochemical approach. Hum Pathol 28: 938-943 1997Google Scholar
  12. 12.
    Keohavong P, DeMichele MA, Melacrinos AC, Landreneau Weyant RJ, Siegfried JM: Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res 2: 411-418, 1996Google Scholar
  13. 13.
    Wang YC, Lee HS, Chen SK, Yang SC, Chen CY: Analysis of K-ras gene mutations in lung carcinomas: correlation with gender, histological subtypes, and clinical outcome. J Cancer Res Clin Oncol 124: 517-522, 1998Google Scholar
  14. 14.
    Huang CL, Taki T, Adachi M, Konishi T, Higashiyama M, Kinoshita M, Hadama T, Miyake M: Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer. Int J Oncol 12: 553-563, 1998Google Scholar
  15. 15.
    Papsidero LD, Croghan GA, Asirwatham J, Gaeta J, Abenoza P, Englander L, Valenzuela L: Immunohistochemical demonstration of prostate-specific antigen in metastases with the use of monoclonal antibody F5. Am J Pathol 121: 451-454, 1985Google Scholar
  16. 16.
    Gown AM, Vogel AM, Hoak D, Gough F, McNutt MA: Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 123: 195-203, 1986Google Scholar
  17. 17.
    Devebec M: Management of patients with brain metastases of unknown origin. Neoplasma 37: 601-606, 1990Google Scholar
  18. 18.
    Khansur T, Routh A, Hickman B: Brain metastases from unknown primary site. J Miss State Med Assoc 38: 238-242, 1997Google Scholar
  19. 19.
    Haman G, Meier T, Schimrigk K: Hirnmetastasen als Erstmanifestation einer Tumorerkrankung. Nervenartz 64: 104-107, 1993Google Scholar
  20. 20.
    Ellis IO, Hitchcock A: Tumor marker immunoreactivity in adenocarcinoma. J Clin Pathol 41: 1064-1067, 1988Google Scholar
  21. 21.
    Hainsworth JD, Wright EP, Johnson DH, Davis BW, Greco FA: Poorly differentiated carcinoma of unknown primary site: clinical usefulness of immunoperoxidase staining. J Clin Oncol 9: 1931-1938, 1991Google Scholar
  22. 22.
    Loy TS, Chapman RK, Diaz-Arias AA, Bulatao IS, Bickel JT: Distribution of BCA-225 in adenocarcinomas. An immunohistochemical study of 446 cases. Am J Clin Pathol 96: 326-329, 1991Google Scholar
  23. 23.
    Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP: Carcinoembryogenetic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 57: 327-334, 1989Google Scholar
  24. 24.
    Hammarstrom S: The carcinoembryogenetic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Sem Cancer Biol 9: 67-81, 1999Google Scholar
  25. 25.
    Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancer. Science 253: 49-53, 1991Google Scholar
  26. 26.
    Horio Y, Takahashi T, Kuroishi T, Hibi K, Suyama M, Niimi T, Shimokata K, Yamakawa K, Ueda R et al.: Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1: 1-4, 1993Google Scholar
  27. 27.
    Barbareschi M, Iuzzolino P, Pennella A, Allegranza A, Arrigoni G, Palma PD, Doglioni C: p53 protein expression in central nervous system neoplasms. J Clin Pathol 45: 583-586, 1992Google Scholar
  28. 28.
    Koga H, Zhang S, Kumanishi T, Washiyama K, Iichikawa T, Tanaka R, Mukawa J: Analysis of p53 gene mutations in low-and high-grade astrocytomas by polymerase chain reaction-assisted single-strand conformation polymorphism and immunohistochemistry. Acta Neuropathol 87: 225-232, 1994Google Scholar
  29. 29.
    Schiffer D, Cavalla P, Di Sapio A, Giordana MT, Mauro A: Mutations and immunohistochemistry of p53 and proliferation markers in astrocytic tumors of childhood. Child's Nerv System 11: 517-522, 1995Google Scholar
  30. 30.
    Nemunaitis J, Klemow S, Tong A, Courtney A, Johnston W, Jack M, Taylor W, Solano M, Stone M, Mallams J, Mues G: Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung. Am J Clin Oncol 21: 155-160, 1998Google Scholar

Copyright information

© Kluwer Academic Publishers 2000

Authors and Affiliations

  • Maria Teresa Giordana
    • 1
  • Susanna Cordera
    • 1
  • Andrea Boghi
    • 1
  1. 1.Department of NeuroscienceUniversity of TurinTurinItaly

Personalised recommendations